HIV is still an important issue in Canada. There is currently no cure, and the number of people infected rises each year.
For over 30 years, CANFAR has worked steadily to advance the fight against HIV/AIDS through funding the highest quality research. Since its inception, CANFAR has invested more than $22 million in HIV/AIDS research projects, and awarded in close to 500 research projects, across Canada.
CANFAR-funded research achievements include findings in all key sectors of HIV, including: prevention, treatment, care, and the search for a cure. Some of our advances include research that has nearly eliminated mother-to-child transmission of HIV, discovery of a key component of the current medication, and leading work for the prevention of new HIV infections transmitted within diverse Canadian populations.
To ensure successful research and optimal allocation of funds, CANFAR has a set of research priorities. They are the following:
1. Provide funding for top quality HIV research projects by Canadian researchers and institutions related to all aspects of HIV and AIDS.
2. Empower and train new researchers as they enter the HIV research field.
The HIV research field needs new ideas, and new people to bring these ideas forward. As new doctorates enter the field, they will have CANFAR’s support in order to dedicate their full potential towards profound new HIV research.
3. Recognize and reward exceptional Canadian HIV researchers.
It is important to recognize the achievements of those brilliant and exceptional individuals who advance the HIV field. CANFAR recognizes and rewards visionaries in the HIV research field in many ways.
4. Improve the understanding of HIV prevention in Canadian gay, bisexual and other men who have sex with men.
Men who have sex with men (MSM) are a high risk population, and therefore prevention is key for this population. CANFAR dedicates funds each year specifically for this purpose.
5. Optimize the understanding of Pre-exposure prophylaxis (PrEP) for Canadian populations and improve delivery and access.
PrEP is a revolutionary new drug regime that targets high-risk populations for prevention. Despite having a potentially tremendous impact, it is still very new, and research about it is necessary to implement it effectively. Thus, CANFAR is prioritizing research in this area.